GlassScriptPhysician profile
Seemal Faisal
NPI 1659934446
$3,807.53
in general payments reported to CMS, 2019-2025
18 companies · $2,460 in 2025
The $2,460 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $259 · 2024: $1,088 · 2025: $2,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,326 · Travel and Lodging: $382 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,326.04 |
| Travel and Lodging | $381.50 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $948.53 | 2024-2025 | |
| Amgen INC. | $510.69 | 2024-2025 | Tavneos, Evenity, Repatha |
| Abbvie INC. | $421.51 | 2024-2025 | |
| Ucb, INC. | $334.41 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $263.01 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $238.73 | 2024-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $228.81 | 2024-2025 | Lupkynis |
| Janssen Scientific Affairs, LLC | $204.95 | 2024-2025 | Tremfya |
| Pfizer INC. | $155.38 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.42 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Janssen Biotech, INC. | $56.95 | 2024-2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $45.73 | 2025 | Strensiq |
| Glaxosmithkline, LLC. | $39.98 | 2024-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $39.90 | 2025 | Sotyktu |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $32.54 | 2024 | Idacio |
| Kyowa Kirin, INC. | $28.66 | 2025 | |
| Octapharma USA, INC. | $20.34 | 2024 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seemal Faisal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.